BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Authorization comes a week after an FDA panel recommended against everyone already vaccinated getting the booster.

FDA approves Pfizer booster shots for those over 65 and at-risk adults

The U.S. has moved a step closer to offering booster doses of Pfizer's PFE, +0.07% COVID-19 vaccine to seniors and others at high risk from the virus.

FDA approves Pfizer COVID-19 boosters for seniors, those at high risk

The FDA greenlit a third dose of Pfizer's coronavirus vaccine for seniors, people with underlying health conditions and people with “occupational exposure” to the coronavirus.

FDA Authorizes Pfizer Covid Booster Shots For Seniors And High-Risk Patients — But Not For All Americans

The hope is that booster shots will help protect those most at risk as the pandemic continues to rage.

FDA authorizes boosters of the Pfizer-BioNTech coronavirus vaccine for older adults and others at high risk from COVID-19

The CDC's vaccine advisory committee plans to meet this week, and the agency's panel of experts is expected to vote on plans to distribute third shots.

FDA authorizes Pfizer's Covid booster shots for people 65 and older and other vulnerable Americans

A committee that advises the Centers for Disease Control and Prevention begins a two-day meeting that likely will end with detailed recommendations on how the U.S. should roll out booster doses of Pfizer's vaccine.

CDC Committee to Consider Pfizer Booster Today. What to Know.

The deal doubles the country's existing commitment and brings the total number of doses it says it will share to 1 billion.

U.S. To Donate 500 Million More Pfizer Vaccine Doses To Poorer Countries

CDC Committee to Consider Pfizer Booster Today. Here's What to Know.

A Centers for Disease Control and Prevention committee is set to meet Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE BNTX, +0.69% and Pfizer Inc.'s PFE, -0.63% COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters be limited to older people and those who are at higher risk of severe disease.

CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 booster

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) will provide the U.S. government additional 500 million doses of its COVID-19 vaccine. The doses at a not-for-profit price will be used for donations to low- and lower-middle-income countries and the organizations that support them.

US To Donate Additional 500M Pfizer-BioNTech COVID-19 Vaccine Doses To Lower Income Nations

Pfizer Inc. PFE, -0.63% and BioNTech SE BNTX, +0.69% announced Wednesday plans to provide an additional 500 million doses of their COVID-19 vaccine to the U.S. government. The additional doses will be sold at "not-for-profit" prices, for donation to low- and lower-middle-income countries, as defined by Gavi's COVAX Advanced Market Commitment (AMC) and the 55 member states of the African Union.

Pfizer, BioNTech to provide additional 500 million COVID-19 vaccine doses to U.S. government for donation

Pfizer and BioNTech will provide an additional 500 million doses of their Covid-19 vaccine to the U.S. government to be donated to lower income countries.

U.S. to donate millions more Pfizer-BioNTech vaccine doses to poorer nations

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies' COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countrie

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries

Citing people familiar with the matter, Bloomberg reports that the FDA is expected to decide on Wednesday whether to recommend Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine as a booster shot. Last Friday, an FDA advisory panel recommended against the broader use of the vaccine as an additional shot.

FDA To Probably Decide On Pfizer/BioNTech COVID-19 Booster Shots By Tomorrow: Bloomberg

Ultimately, BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place.

For BioNTech, the COVID-19 vaccine was simply the opening act

Bausch Health Companies Inc

Biogen

CRISPR Therapeutics

Moderna

Teva Pharmaceutical

Vertex Pharmaceuticals

Viatris

SPDR S&P Pharmaceuticals ETF

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

Former FDA Commissioner Dr. Mark McClellan explains why he thinks it's realistic that younger children will be able to get the Covid vaccine by Halloween.

FDA-approved Covid vaccine for kids ages 5 to 11 ‘very feasible' by Halloween, says former FDA commissioner

How quickly we go from today's announcement to shots in little arms depends on how smoothly the process unfolds. Announcing impressive results from a Phase 2/3 trial on Monday, Pfizer and BioNTech said their two-dose COVID-19 vaccine works very well on children aged 5 to 11, a potential game-changer for people in that age group, their parents and caregivers, and vaccination efforts across the country.

When can children get the COVID vaccine? Good Pfizer-BioNTech results could mean fast timeline

Alibaba

Caterpillar

Goldman Sachs

September Syndrome Deepens in Markets

Pfizer, Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) suffered a setback last week after a FDA panel did not recommend a third dose of the duo's COVID-19 vaccine for the broader population. The Pfizer-BioNTech Analysts: Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating and $45 price target for Pfizer shares.

Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision

It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.

Contagion Fears Squeeze Pre-Market Futures

Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.

FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from one cohort from a Phase 2/3 trial evaluating its COVID-19 vaccine on a two-dose schedule (approximately 21 days apart). The data from over 2,200 children aged 5 to 11 years showed a favorable safety profile and robust neutralizing antibody responses using a two-dose regimen of 10 µg, a smaller dose than the 30 µg dose used for people 12 and older.

Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know

Pfizer and BioNTech's intend to apply for approval for their Covid-19 vaccine to be given to children after a trial showed it to be safe and rapidly built up resistance to the virus. Children received two doses of the vaccine 21 days apart in what was the first major trial of a covid vaccine for those under the age of 12, Antibody responses in the participants were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with three times larger doses, said the firms.

Pfizer and BioNTech to seek approval to vaccinate children after Covid study

NEW YORK AND MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older. The antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfiz

News for BioNTech SE Stock (BNTX)